Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,803 total articles
Verizon (VZ) offers a compelling long trade: a dividend yield north of 6%, roughly $20.1B in annual free cash flow, and a sub-11x P/E valuation. Technicals are oversold, providing an entry opportunity near $45.03. Target $52 and stop $42 on a long-term horizon (46-180 trading days).
Lucid ($LCID) is a high-risk, high-reward recovery trade. A nascent robotaxi partnership plus visible BOM-cost reduction initiatives create a path to materially better per-vehicle margins. At a market cap near $2.7B and heavy short interest, the stock can re-rate quickly on execution beats. Entry $8.25, target $11.65, stop $6.50. Time horizon: long…
Talos Energy (TALO) has underappreciated, near-term upside tied to Gulf of Mexico production optionality and a favorable oil price backdrop. We recommend a long trade that targets a re-rating on stronger macro crude and operational catalysts while keeping a disciplined stop to limit downside from the sector’s well-known shocks.
Microsoft is morphing from a software vendor into an "intelligence refinery" that monetizes compute, data and productivity workflows. With a $3.05T market cap, strong free cash flow and a low leverage profile, the stock is a pragmatic long trade: entry $418.02, target $520.00, stop $390.00 on a long-term (180 trading days) horizon.
Teledyne's unique mix of high-performance imaging, instrumentation and aerospace electronics earns a premium multiple. Solid free cash flow, low leverage, and structurally advantaged end markets make the stock buyable on a disciplined pullback. Entry, stop and targets provided for three horizons.
Sea (SE) has been punished despite a record $22.9B in 2025 revenue and a $1.6B net profit. At a $53.5B market cap, the stock only needs earnings to expand toward $2.4B for a 22x P/E to be justified. With momentum turning constructive and multiple near-term catalysts, we upgrade to Long with a defined entry, stop, and target for a long-term trade (1…
Electro Opic Sys Ltd (EOPSF) is trading above its key moving averages with bullish MACD/RSi and an explosive increase in short interest through 03/31/2026. For nimble traders willing to accept elevated risk and OTC illiquidity, an entry near the last close offers a defined risk-reward: entry $7.64, stop $5.50, target $12.00 over a mid-term window o…
Northrop Grumman is uniquely positioned to capture decades of priority spending on strategic deterrent modernization, space domain awareness and orbital defense. Recent B-21 flight-test progress and acceleration of the Sentinel ICBM program, combined with a cash-generative business and strong returns on equity, make a long trade at $678.59 compelli…
Nissan (NSANY) looks actionable after a string of investor events and partner announcements that materially lower execution risk on electrification and software partnerships. At a $8.4B market cap and a price near the 52-week low, the stock trades cheaply on book (PB ~0.25) while technical momentum is leaning constructive. This trade targets a mid-…
Alliance Resource Partners (ARLP) trades like a deeply discounted cash generator. At roughly $25.71 today, the partnership yields near 10% and sits on free cash flow of roughly $388M — metrics that make speculative exposure to its rumored pivot into AI infrastructure, bitcoin, or electrification technology inexpensive. This trade targets a reversio…
Oshkosh (OSK) has retraced from its February highs and is trading at an earnings-backed valuation with a visible path to higher free cash flow. The stock looks tradable to the long side over the next 45 trading days: favorable defense demand, solid FCF, and a reasonable balance sheet support upside to $165. That said, macro headwinds — higher rates…
Paul Mueller Co. reported a strong Q4 and a materially larger backlog, setting up a tactical long. Liquidity is thin and upside may already be partially reflected, so this is a measured, medium-risk swing trade with defined entry, stop and target.
Amdocs (DOX) is trading near its 52-week low while generating meaningful free cash flow and carrying low leverage. The combination of recurring software/managed services revenue, telecom modernization catalysts and a modest valuation (P/E ~14, EV/EBITDA ~8.5) supports a tactical long over the next 45 trading days with a clear stop and a target near…
COPEL's core businesses - generation, transmission and distribution - offer steady cash flow and a path to recovery that, in our view, is not fully reflected in the current pricing. This trade sets a clear entry, stop and target to capture asymmetric upside while limiting downside exposure.
Dollar Tree is set to benefit from a renewed 'trade down' in consumer spending amid higher energy and living costs. Fundamentals show steady revenue growth, strong free cash flow and an attractive multi-price rollout that is boosting ticket averages. Valuation is reasonable for a high-return-on-equity retailer. I recommend a tactical long at $101.3…
Helios Technologies (HLIO) looks set to recover after a volatile 2024-2025 cycle. Revenue beats, rising free cash flow and controlled leverage provide a cleaner fundamental backdrop. Combine that with constructive technical momentum and a still-reasonable valuation and you get a defined trade with asymmetric upside over the next 45 trading days.
Global X Uranium ETF (URA) offers concentrated exposure to uranium miners and nuclear suppliers at $54.84. Momentum indicators are bullish, short interest has compressed, and uranium fundamentals (prices and policy) are supportive. Trade idea: buy URA at $54.00, stop $50.50, target $62.28 over a mid-term (45 trading days) horizon.
Energy Vault (NRGV) has moved from breakthrough demonstrations to real projects and asset-backed funding. Recent contract wins and a sizable capital stack for Asset Vault create a path toward positive EBITDA; the trade plan targets $5.50 with a $2.90 stop on a long-term (180 trading days) horizon.
Willis Lease Finance (WLFC) is upgraded to Strong Buy. Recent engine-focused lease growth, record 2025 revenue of $730M and robust free cash flow ($252M) create a favorable risk-reward despite leverage and governance headlines. Entry $210.15, target $270, stop $185 over a 180-trading-day horizon.
Dutch Bros (BROS) remains one of the fastest-growing drive-thru coffee chains in the U.S., with high average unit volumes, healthy shop-level margins and a sticky loyalty program. The stock has corrected from its highs and offers a mid-term trading opportunity while the business proves it can scale without eroding unit economics. Initiate a tactica…
Universal Health Services (UHS) is trading at roughly 8x reported earnings with an enterprise value/EBITDA near 6x and free cash flow of $825M. Balance sheet metrics are reasonable and recent M&A (Talkspace) expands higher-growth outpatient/virtual behavioral exposure. For traders willing to hold for the next 45 trading days, UHS offers a compellin…
Frontdoor's subscription-heavy home service plan business is showing accelerating top-line growth and expanding margins while converting into meaningful free cash flow. The market has treated FTDR like a cyclical name, but recent results and cash generation argue for re-rating. This trade idea targets a move back toward the 52-week high, with a cle…
BioAge’s oral NLRP3 inhibitor BGE-102 is positioned to deliver a binary proof-of-concept readout on cardiovascular (CV) inflammation in 2H26. The company is well-funded after a January offering, carries low debt, and has already demonstrated tolerability and biomarker activity in Phase 1. This trade idea lays out an entry at $17.00, a stop at $12.5…
IonQ jumped sharply after a DARPA contract and a photonic interconnect demo linked two commercial trapped-ion systems. The rally has technical momentum and heavy volume, creating a tactical swing opportunity. This trade idea lays out an entry, stop and target for a mid-term (45 trading days) play while flagging valuation, cash burn and execution ri…
Biohaven's clinical disappointment on troriluzole and a pipeline pivot make the next six months binary. With Phase 2 obesity data due in H2 2026 and other readouts on the docket, the stock has upside if data surprises, but clinical and commercial uncertainty plus elevated short interest argue for a neutral stance. We downgrade to Hold and lay out a…
